Source link : https://www.newshealth.biz/health-news/despite-early-promise-glp-1-disappoints-in-parkinsons/
Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease (PD) enrolled in a phase 3 trial. “The results of this trial have been eagerly anticipated, and the negative results will be a major disappointment to patients affected by […]
Author : News Health
Publish date : 2025-02-07 05:58:59
Copyright for syndicated content belongs to the linked Source.